11Nov
COVID-19 Report for Life Sciences and Health Care Companies (UPDATED)
In Tuesday's Report: the expanding role of real-world evidence in FDA medical device submissions; President-elect Joe Biden lays out COVID-19 plan; Pfizer announces vaccine efficacy; and an analysis of material adverse change (MAC) clauses in Japan....
By:
Hogan Lovells
Related
The Affordable Care Act requires that employer-sponsored group medical insurance plans provide contr...
Read More >
Under the National Labor Relations Act (NLRA), employees have a right of collective action, and empl...
Read More >
In Salladay v. Lev, the Delaware Chancery Court elaborated on how early a corporate board must take ...
Read More >
In 2019, the U.S. Court of Appeals for the Second Circuit made headlines when it ruled that creditor...
Read More >
The need to replenish intellectual property has pushed the pharma industry to the highest-performing...
Read More >
CBInsights recently hosted a webcast, The State of Healthcare Q2 2020. Capital raising by companies ...
Read More >